CRISPR Therapeutics AG (NASDAQ:CRSP) does about 1.09M shares in volume on a normal day but saw 944882 shares change hands in Friday trading. The company now has a market cap of 5.87B USD and an enterprise value of about $6.06B. Its current market price is $85.46, marking a decrease of -1.04% compared to the previous close of $86.36. The 52 week high reached by this stock is $97.82 whilst the lowest price level in 52 weeks is $32.30. The script in recent trading has seen the stock touch a high of $87.34 and a low of $83.53.
CRISPR Therapeutics AG (CRSP) has a 20-day trading average at $90.31 and the current price is -12.64% off the 52-week high compared with 164.58% distance from its 52-week low. The 50-day simple moving average of the closing price is $76.84 and its 200-day simple moving average is $59.62. If we look at the stock’s price movements over the week, volatility stands at 4.76%, which increases to 5.64% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 50.40 to suggest the stock is neutral.
17 analysts observing the CRISPR Therapeutics AG (CRSP) stock have set the 12-month price targets for the company’s shares at between $31.00 and $140.00. The consensus objective for the share price is $81.75, suggesting that the stock has a potential downside of -4.54% over the period. The median price target is 18.22% away from the current levels at $104.50.
FactSet Research has provided data showing that 17 brokerages have issued ratings for the stock. 2 analysts have rated it as a sell, while 0 advise that it is a overweight. 11 analysts have rated it as a buy and 4 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 28, 2020 when Needham reiterated the stock to “Buy” and issued a price target of between $84 and $105. Canaccord Genuity reiterated its price target at $80-$84.
The current price level is -5.07%, 11.76%, and 43.91% away from its SMA20, SMA50, and SMA200 respectively, with the CRSP price moving above the 50-day SMA on July 31. CRISPR Therapeutics AG (CRSP) stock is down -5.41% over the week and 8.87% over the past month. Its price is 40.32% year-to-date and 62.60% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$1.3 below consensus estimates by -$0.35. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at -$1.18 and -$4.79 for whole year. CRSP’s earnings per share are forecast to shrink by -509.40% this year and -5.00% over next year. Expected sales for next quarter are $2.85 million, which analysts say will come at $4.88 million for the current fiscal year and next year at $18.47 million. In addition, estimates put the company’s current quarterly revenue at an average of $2.22 million.
Its 12-month price target is $104.50. To reach the target analysts have set, the stock logically needs to shrink -4.54 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $31.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $140.00.
Outstanding shares total 60.85M with insiders holding 20.94% of the shares and institutional holders owning 55.73% of the company’s common stock. The company has a return on investment of 4.90% and return on equity of 6.50%. The price to earnings ratio (P/E ratio) amounts to 113.34. The beta has a value of 2.37. Price to book ratio is 5.87 and price to sales ratio is 20.30.
According to a U.S. Securities and Exchange Commission filing, ARK Innovation ETF has added its position in CRISPR Therapeutics AG (CRSP) to 3,951,069 shares, mirroring a recent increase by 0.49%. ARK Innovation ETF added 19383.0 shares of CRISPR Therapeutics AG common stock bringing its total worth to about $290.36 million at the end of recent close, SEC documents show. ARK Innovation ETF isn’t the only investment manager who changed stakes and is followed by Nikko AM Global Umbrella Fund – A, which added 2.06 million shares to end up with 2,079,677 shares worth $152.84 million. ARK Genomic Revolution ETF raise their holdings by 0.74% in the company over the course of the most recent quarter. It now holds a 2.75% position in CRISPR Therapeutics AG thanks to 1.88 million shares amounting to $138.25 million.